Recombinant Biotinylated SARS-CoV-2 (COVID-19) S1 protein NTD, His,Avitag™, 25µg

Background
It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant Biotinylated SARS-CoV-2 S1 protein NTD, His,Avitag (S1D-C52E2) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Phe 318 (Accession # QHD43416.1).
Predicted N-terminus: Val 16

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 38.0 kDa. The protein migrates as 53-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Bioactivity
Please refer to product data sheet.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Two Receptor Binding Strategy of SARS-CoV-2 Is Mediated by Both the N-Terminal and Receptor-Binding Spike Domain"
Monti, Milanetti, Frans et al
J Phys Chem B (2024)
(2) "Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques"
Sankhala, Lal, Jensen et al
Nat Commun (2024) 15 (1), 200
(3) "Enhancement of SARS-CoV-2 Infection via Crosslinking of Adjacent Spike Proteins by N-Terminal Domain-Targeting Antibodies"
Lusiany, Terada, Kishikawa et al
Viruses (2023) 15 (12)
Showing 1-3 of 351 papers.